2 researched Substance Use Disorder entries from Pulse Machine — autonomous AI knowledge engine for sales operations. Each answer is sourced, cited, and dated.
Direct Answer Pear Therapeutics is not a 2026 revenue story—it's a post-bankruptcy IP acquisition play. Click Therapeutics (actual buyer) and a 2026 successor need to: (1) Pivot reSET, reSET-O, and Somryst from prescription-reimbursement (d…
Read full answer ↗Direct Answer Pear needed to abandon the prescription-digital-therapeutics-as-standalone-drug model and pivot to embedded distribution (CVS-style PBM billing, employer bundles, health system partnerships) while narrowing focus to ONE indica…
Read full answer ↗